Jorge Riera Knorrenschild

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI

Salah‐Eddin Al‐Batran, Thorsten Oliver Goetze, Daniel Mueller et al. · BMC Cancer · 2017 · 218 citations · Full text

Breaking bad news–what patients want and what they get: evaluating the SPIKES protocol in Germany

Carola Seifart, Mareike Hofmann, Tordis Bär et al. · Annals of Oncology · 2014 · 171 citations · Full text

Health Systems, Health Policy, Health Outcome +5

HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study

Ivonne Haffner, Katrin Schierle, Elba Raimúndez et al. · Journal of Clinical Oncology · 2021 · 112 citations · Full text

Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)

Thomas Ruhstaller, Peter Thuss‐Patience, Stefanie Hayoz et al. · Annals of Oncology · 2018 · 102 citations · Full text

Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.

Salah-Eddin Al-Batran, Sylvie Lorenzen, Peter Thuss‐Patience et al. · Journal of Clinical Oncology · 2022 · 94 citations

Surgical Oncology, Esophageal Cancer, Cancer Management +19